Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

Conditions: Unresectable Metastatic Colorectal Cancer Interventions: Drug: ABBV-400; Drug: Bevacizumab; Drug: Folinic Acid; Drug: Fluorouracil; Drug: Irinotecan Sponsors: AbbVie Not yet recruiting

https://clinicaltrials.gov/study/NCT06107413

Source: ClinicalTrials.gov - October 30, 2023 Category: Research Source Type: clinical trials